Table 3 Pembrolizumab response in patients with microsatellite instability-high cancers and discordant immunohistochemical mismatch repair protein expression results.

From: Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes

CBioPortal ID

Time on pembrolizumab

Best response

Reason for discontinuation

P-0013462

35 months

Complete response

Stopped after 3 years/course completed

P-0012115

12 months

Partial response

Stopped after 1 year/course completed

P-0019598

24 months

Stable disease

Treatment is ongoing

Back to article page